Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) is trading at over 20% pre-market as of 8:22 AM ET. This is why it happened.

INO Stock Price Increases Over 20% Pre-Market: Why It Happened

Once a leader in the COVID-19 vaccine race, does this biotech have what it takes to deliver market-shattering returns?

Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?

Reddit investors are sure hyped up about shares of this biotech underdog. Should you be as well?

Is Now the Time to Buy Inovio Stock?

In less than several weeks, Inovio Pharmaceuticals (NASDAQ: INO) shares have advanced from $8.8 to $19, and the current price stands around $15. Inovio Pharmaceuticals has signed an agreement with Advaccine Biopharmaceuticals, and the positive news is that BlackRock increased its ownership in this company.

Should I invest in Inovio Pharmaceuticals shares in February?

BlackBerry

Bionano Genomics

One of the most common questions traders have about stocks is “Why Is It Moving?”.

Here's Why BioNano Genomics, Inovio And Blackberry Are Moving

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) is trading at more than 12% pre-market today as of 8:51 AM. This is why it happened.

INO Stock Price Increases Over 12% Pre-Market: Why It Happened

Arcturus Therapeutics

Vaxart

Probably not, if you're investing for the long term.

Is It Too Late to Buy These 3 COVID Vaccine Latecomer Stocks?

Inovio Pharmaceuticals surged Monday on a Reddit call to action and after investment firm BlackRock upped its stake in the biotech company. INO stock soared to a five-month high.

Inovio Surges On Reddit Call To Action As Investment Firm Boosts Stake

Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

Reddit Users Are Targeting This Covid Vaccine Maker — Is INO Stock A Buy?

AMC Entertainment

GameStop

American Airlines

Blink Charging

Nikola

Virgin Galactic

Tilray Brands

TherapeuticsMD

Workhorse Group

Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.

10 Robinhood Stocks With the Highest Short Interest

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) increased by 16.44% on Friday, January 29. This is why it happened.

INO Stock Price Increased 16.44%: Why It Happened

INO is one of the most highly shorted biotechs and among the top 25 stocks in terms of short interest listed on the NASDAQ/AMEX/NYSE. INO has recently raised funds and is planning to start a phase 3 study of the company's COVID-19 vaccine.

Why Inovio Pharmaceuticals Could Be Headed For A GameStop-Like Short Squeeze

ARK Innovation ETF

HEXO Corp

None of them outperformed the cryptocurrency in 2020, but that could change this year.

3 Popular Robinhood Stocks That Could Be Better Than Bitcoin in 2021

Amyris

Clean Energy Fuels

GenMark Diagnostics

Himax Tech

Sunopta

United Microelectronics

Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Growth In 2021 appeared first on InvestorPlace.

7 Great Cheap Stocks To Buy For Solid Growth In 2021

PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated...

INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

CytomX Therapeutics

Editas Medicine

All four biotechs announced the pricing of stock offerings.

Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today

Shares of Inovio Pharmaceuticals Inc. were down 5.1% in premarket trading on Thursday, the day after the company announced a public offering of 17,700,000 shares at $8.50 per share. The stock closed Wednesday at $9.72.

Inovio's stock falls after it announces public offering

PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated...

INOVIO Announces Pricing of Public Offering of Common Stock

INOVIO Announces Proposed Public Offering of Common Stock

The biotech company's COVID-19 vaccine candidate may not be near the finish line, but that doesn't mean investors should count it out just yet.

Is Inovio Pharmaceuticals a Buy?

argenx

EyePoint Pharmaceuticals

Gilead Sciences

Gracell Biotechnologies

Eli Lilly

Paratek Pharma

Zai Lab Ltd.

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive efficacy...

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.

Don't Sleep on Inovio Pharmaceuticals as a Serious Vaccine Contender

Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against the novel coronavirus, were advancing Monday. What Happened: Plymouth Meeting, Pennsylvania-based Inovio announced a collaboration and licensing agreement with China-based biotech Advaccine Biopharma to market its investigational vaccine INO-4800 in the Greater China region.

Inovio Strikes $100M Coronavirus Vaccine Licensing Deal With China's Advaccine

Shares of Inovio Pharmaceuticals Inc. were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-19 vaccine candidate.

Inovio to partner with Chinese biotech on COVID-19 vaccine candidate in Greater China

News for Inovio Pharmaceuticals Stock (INO)